DJIA 16,235.13 176.78 1.10%
NASDAQ 4,689.03 52.93 1.14%
S&P 500 1,933.87 20.02 1.05%
market minute promo


148.50 1.04 (0.71%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

AMGN $148.39 0.63%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $149.07
Previous Close $147.46
Daily Range $147.25 - $151.40
52-Week Range $127.67 - $181.81
Market Cap $112.6B
P/E Ratio 19.53
Dividend (Yield) $3.16 (2.1%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,729,106
Average Daily Volume 4,213,385
Current FY EPS $9.72




Drug Makers

Amgen (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website:

News & Commentary

Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern

Repatha gets the green light from the Food and Drug Administration, but pharmacy benefit managers and insurers are ready to give PCSK9 inhibitors the red light.

Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?

Notable ETF Outflow Detected - XLV, GILD, AGN, AMGN

Premarket Biotech Digest: Anti-CD Antigen Therapy, Geron Files S-3, 3 MAAs In EU

Sept. 2 Premarket Briefing: 10 Things You Should Know

26 Stocks For September 2015

Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor

A Word of Advice for Amgen: Objects in the Mirror Are Closer Than They Appear

Amgen's multiple myeloma drug Kyprolis recently had its label expanded, but sales growth is no guarantee, especially with a Johnson & Johnson experimental drug waiting in the wings.

Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept

Amgen Poised To Dominate A $32 Billion Biosimilar Market

See More AMGN News...

AMGN's Top Competitors

AMGN $148.50 (0.71%)
Current stock: AMGN
GILD $101.74 (0.25%)
Current stock: GILD
CELG $117.03 (1.36%)
Current stock: CELG
$0.00 (0.00%)
Current stock: